[1] Chen W. Cancer statistics: updated cancer burden in China[J]. Chin J Cancer Res, 2015, 27(1): 1. DOI: 10.3978/j.issn.1000-9604.2015.02.07.
[2] Nakamoto Y, Guidotti LG, Kuhlen CV, et al. Immune pathogenesis of hepatocellular carcinoma[J]. J Exp Med, 1998, 188(2): 341-350.
[3] Rogler G. Chronic ulcerative colitis and colorectal cancer[J]. Cancer Lett, 2014, 345(2): 235-241. DOI: 10.1016/j.canlet.2013.07.032.
[4] Komurcuoglu B, Ulusoy S, Gayaf M, et al. Prognostic value of plasma D-dimer levels in lung carcinoma[J]. Tumori, 2011, 97(6): 743-748. DOI: 10.1700/1018.11091.
[5] Unsal E, Atalay F, Atikcan S, et al. Prognostic significance of hemostatic parameters in patients with lung cancer[J]. Respir Med, 2004, 98(2): 93-98.
[6] Chew V, Chen J, Lee D, et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining longterm survival in resectable hepatocellular carcinoma[J]. Gut, 2012, 61(3): 427-438. DOI: 10.1136/gutjnl-2011-300509.
[7] Matsuoka K, Sumitomo S, Nakashima N, et al. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage Ⅰ non-small cell lung cancer[J]. Eur J Cardiothorac Surg, 2007, 32(3): 435-439. DOI: 10.1016/j.ejcts.2007.05.014.
[8] 姚晓军, 刘伦旭. 肺癌的流行病学及治疗现状[J]. 现代肿瘤医学, 2014, 22(8): 1982-1986. DOI: 10.3969/j.issn.1672-4992.2014.08.74.
[9] Tartour E, Zitvogel L. Lung cancer: potential targets for immunotherapy[J]. Lancet Respir Med, 2013, 1(7): 551-563. DOI: 10.1016/S2213-2600(13)70159-0.
[10] 陈悦, 肖苏, 潘伟. 术前新辅助化疗在宫颈癌行手术治疗患者中的应用[J]. 国际肿瘤学杂志, 2017, 44(10): 749-753. DOI: 10.3760/cma.j.issn.1673-422X.2017.10.007.
[11] Kaplan M, Ates I, Oztas E, et al. A new marker to determine prognosis of acute pancreatitis: PLR and NLR combination[J]. J Med Biochem, 2018, 37(1): 21-30. DOI: 10.1515/jomb-2017-0039.
[12] 石朋, 赵毅, 邓鑫. 术前中性粒细胞淋巴细胞比率(NLR)预测胃癌预后的临床意义[J]. 现代肿瘤医学, 2012, 20(5): 987-991. DOI: 10.3969/j.issn.1672-4992.2012.05.37.
[13] Templeton AJ, Ace O, Mcnamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23(7): 1204-1212. DOI: 10.1158/1055-9965.EPI-14-0146.
[14] Zhang Y, Wang L, Liu Y, et al. Preoperative neutrophil-lymphocyte ratio before platelet-lymphocyte ratio predicts clinical outcome in patients with cervical cancer treated with initial radical surgery[J]. Int J Gynecol Cancer, 2014, 24(7): 1319-1325. DOI: 10.1097/IGC.0000000000000219.
[15] Kemal Y, Yucel I, Ekiz K, et al. Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis[J]. Asian Pac J Cancer Prev, 2014,15(6): 2651-2654.
[16] Cukic V. Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with NSCLC[J]. Mater Sociomed, 2016, 28(5): 378-381. DOI: 10.5455/msm.2016.28.378-381.
[17] Ozyalvacli G, Yesil C, Kargi E, et al. Diagnostic and prognostic importance of the neutrophil lymphocyte ratio in breast cancer[J]. Asian Pac J Cancer Prev, 2014, 15(23): 10363-10366. |